{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Cytokines", "Inflammation", "Licofelone", "ROS", "Ulcerative colitis"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37233919", "DateCompleted": {"Year": "2023", "Month": "10", "Day": "23"}, "DateRevised": {"Year": "2024", "Month": "01", "Day": "24"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "05", "Day": "26"}], "Language": ["eng"], "ELocationID": ["10.1007/s10753-023-01835-0"], "Journal": {"ISSN": "1573-2576", "JournalIssue": {"Volume": "46", "Issue": "5", "PubDate": {"Year": "2023", "Month": "Oct"}}, "Title": "Inflammation", "ISOAbbreviation": "Inflammation"}, "ArticleTitle": "Licofelone Attenuates Acetic Acid-Induced Colitis in Rats Through Suppression of the Inflammatory Mediators.", "Pagination": {"StartPage": "1709", "EndPage": "1724", "MedlinePgn": "1709-1724"}, "Abstract": {"AbstractText": ["Licofelone is a dual Cyclooxygenase 1,2 (COX1,2)/5-lipoxygenase) 5-LOX (inhibitor with analgesic and anti-inflammatory effects with possible functions on inflammatory bowel disease (IBD), which is a chronic recurrent condition with no particular treatment. This study evaluated the anti-inflammatory effects of licofelone on acetic acid-induced colitis in rats. Ten groups of male Wistar rats (n = 6) were used. Sham, control group, licofelone at doses of 2.5, 5, and 10 mg/kg, L-NG-nitro arginine methyl ester (L-NAME) (10 mg/kg, i.p.), aminoguanidine (AG) (100 mg/kg, i.p.), 30 min before using licofelone (10 mg/kg). Also, three groups received L-NAME, aminoguanidine, or dexamethasone. Macroscopic, microscopic, and biochemical analysis of myeloperoxidase (MPO), and nuclear factor-kappa B (NF-\u03baB), tumor necrosis factor-\u03b1 (TNF-\u03b1), and interleukin-1\u03b2 (IL-1\u03b2), superoxide dismutase (SOD), reactive oxygen species (ROS), and Toll-like receptor 4 (TLR-4) were assessed in colon tissue. Licofelone at a dose of 10 mg/kg attenuated colitis, increased SOD activity, and significantly reduced colonic levels of the abovementioned inflammatory factors. In addition, licofelone improved macroscopic and microscopic symptoms in the acetic acid-induced colitis model. Moreover, the concurrent use of nitric oxide synthase (NOS) inhibitors with 10 mg/kg of licofelone reversed the observed positive effects, demonstrating the function of nitric oxide in IBD pathogenesis and the probable mechanism for licofelone in the healing process of induced colitis. A reduced level of inflammatory factors confirmed the anti-inflammatory activity of licofelone as a dual COX1,2/5-LOX inhibitor. Furthermore, outcomes revealed the protective role of licofelone in treating experimental colitis. The findings are suggestive of the potential use of licofelone in IBD."], "CopyrightInformation": "\u00a9 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Shariati St, Tehran Medical Sciences, Islamic Azad University, P. O. Box, No. 99, Yakhchal, Gholhak, 19419-33111, Tehran, Iran."}], "LastName": "Shahraki", "ForeName": "Faezeh Niazi", "Initials": "FN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran."}, {"Identifier": [], "Affiliation": "Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), Faculty of Pharmacy, The Institute of Pharmaceutical Sciences (TIPS), and, Tehran University of Medical Sciences , Tehran, Iran."}, {"Identifier": [], "Affiliation": "Gastrointestinal Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran."}], "LastName": "Momtaz", "ForeName": "Saeideh", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), Faculty of Pharmacy, The Institute of Pharmaceutical Sciences (TIPS), and, Tehran University of Medical Sciences , Tehran, Iran."}], "LastName": "Baeeri", "ForeName": "Maryam", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Shariati St, Tehran Medical Sciences, Islamic Azad University, P. O. Box, No. 99, Yakhchal, Gholhak, 19419-33111, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Gastrointestinal Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran."}], "LastName": "Khayatan", "ForeName": "Danial", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Shariati St, Tehran Medical Sciences, Islamic Azad University, P. O. Box, No. 99, Yakhchal, Gholhak, 19419-33111, Tehran, Iran."}], "LastName": "Lashgari", "ForeName": "Naser-Aldin", "Initials": "NA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Shariati St, Tehran Medical Sciences, Islamic Azad University, P. O. Box, No. 99, Yakhchal, Gholhak, 19419-33111, Tehran, Iran."}], "LastName": "Roudsari", "ForeName": "Nazanin Momeni", "Initials": "NM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pathology, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran."}], "LastName": "Abdollahi", "ForeName": "Ali Reza", "Initials": "AR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. dehpour@yahoo.com."}, {"Identifier": [], "Affiliation": "Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. dehpour@yahoo.com."}], "LastName": "Dehpour", "ForeName": "Ahmad Reza", "Initials": "AR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Toxicology & Pharmacology, Faculty of Pharmacy, Shariati St, Tehran Medical Sciences, Islamic Azad University, P. O. Box, No. 99, Yakhchal, Gholhak, 19419-33111, Tehran, Iran. amirhosein172@hotmail.com."}, {"Identifier": [], "Affiliation": "Gastrointestinal Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran. amirhosein172@hotmail.com."}], "LastName": "Abdolghaffari", "ForeName": "Amir Hossein", "Initials": "AH"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Inflammation", "NlmUniqueID": "7600105", "ISSNLinking": "0360-3997"}, "ChemicalList": [{"RegistryNumber": "SCQ4EZQ113", "NameOfSubstance": "pimagedine"}, {"RegistryNumber": "Q40Q9N063P", "NameOfSubstance": "Acetic Acid"}, {"RegistryNumber": "P5T6BYS22Y", "NameOfSubstance": "licofelone"}, {"RegistryNumber": "V55S2QJN2X", "NameOfSubstance": "NG-Nitroarginine Methyl Ester"}, {"RegistryNumber": "0", "NameOfSubstance": "Inflammation Mediators"}, {"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents"}, {"RegistryNumber": "EC 1.15.1.1", "NameOfSubstance": "Superoxide Dismutase"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Acetic Acid"}, {"QualifierName": [], "DescriptorName": "Rats, Wistar"}, {"QualifierName": [], "DescriptorName": "NG-Nitroarginine Methyl Ester"}, {"QualifierName": [], "DescriptorName": "Inflammation Mediators"}, {"QualifierName": ["chemically induced", "drug therapy"], "DescriptorName": "Colitis"}, {"QualifierName": ["chemically induced", "drug therapy"], "DescriptorName": "Inflammatory Bowel Diseases"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Anti-Inflammatory Agents"}, {"QualifierName": [], "DescriptorName": "Superoxide Dismutase"}, {"QualifierName": ["chemically induced"], "DescriptorName": "Colitis, Ulcerative"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Yadav, V., et al. 2016. Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets. Translational Research 176: 38\u201368.", "ArticleIdList": ["10.1016/j.trsl.2016.04.009", "27220087"]}, {"Citation": "Marafini, I., et al. 2019. Inflammatory cytokines: from discoveries to therapies in IBD. Expert Opinion on Biological Therapy 19 (11): 1207\u20131217.", "ArticleIdList": ["10.1080/14712598.2019.1652267", "31373244"]}, {"Citation": "Rohr, M., et al. 2018. Inflammatory diseases of the gut. Journal of Medicinal Food 21 (2): 113\u2013126.", "ArticleIdList": ["10.1089/jmf.2017.0138", "29389238"]}, {"Citation": "Lashgari, N.-A., et al. 2021. Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations. Molecular Biology Reports 48 (1): 855\u2013874.", "ArticleIdList": ["10.1007/s11033-020-06095-x", "33394234"]}, {"Citation": "Lashgari, N.-A., et al. 2021. Targeting mammalian target of rapamycin: prospects for the treatment of inflammatory bowel diseases. Current Medicinal Chemistry 28 (8): 1605\u20131624.", "ArticleIdList": ["32364064"]}, {"Citation": "M\u00fcnch, A., and C. Langner. 2015. Microscopic colitis: clinical and pathologic perspectives. Clinical Gastroenterology and Hepatology 13 (2): 228\u2013236.", "ArticleIdList": ["10.1016/j.cgh.2013.12.026", "24407107"]}, {"Citation": "Kuenzig, M.E., et al. 2022. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology 162 (4): 1147-1159.e4.", "ArticleIdList": ["10.1053/j.gastro.2021.12.282", "34995526"]}, {"Citation": "Lashgari, N.-A., et al. 2022. Mammalian target of rapamycin; novel insight for management of inflammatory bowel diseases. World Journal of Pharmacology 11 (1): 1\u20135.", "ArticleIdList": ["10.5497/wjp.v11.i1.1"]}, {"Citation": "Lashgari, N.A., et al. 2021. Ginger and its constituents: role in treatment of inflammatory bowel disease. BioFactors."}, {"Citation": "Razavi, S.M., et al. 2021. Licofelone, a potent COX/5-LOX inhibitor and a novel option for treatment of neurological disorders. Prostaglandins Other Lipid Mediat 157: 106587.", "ArticleIdList": ["10.1016/j.prostaglandins.2021.106587", "34517113"]}, {"Citation": "Eslami, S.M., et al. 2016. Anticonvulsive effects of licofelone on status epilepticus induced by lithium-pilocarpine in wistar rats: a role for inducible nitric oxide synthase. Journal of Epilepsy Research 6 (2): 53.", "ArticleIdList": ["10.14581/jer.16011", "5206100"]}, {"Citation": "Fakhraei, N., et al. 2014. Protective effect of hydroalcoholic olive leaf extract on experimental model of colitis in rat: involvement of nitrergic and opioidergic systems. Phytotherapy Research 28 (9): 1367\u20131373.", "ArticleIdList": ["10.1002/ptr.5139", "24590915"]}, {"Citation": "Saadatzadeh, A., et al. 2012. Biochemical and pathological evidences on the benefit of a new biodegradable nanoparticles of probiotic extract in murine colitis. Fundamental & Clinical Pharmacology 26 (5): 589\u2013598.", "ArticleIdList": ["10.1111/j.1472-8206.2011.00966.x"]}, {"Citation": "Elbaz, E.M., et al. 2023. Donepezil halts acetic acid-induced experimental colitis in rats and its associated cognitive impairment through regulating inflammatory/oxidative/apoptotic cascades: an add-on to its anti-dementia activity. International immunopharmacolog 116."}, {"Citation": "Morris, G.P., et al. 1989. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96 (2): 795\u2013803.", "ArticleIdList": ["10.1016/S0016-5085(89)80079-4", "2914642"]}, {"Citation": "Stumhofer, J.S., et al. 2006. Interleukin 27 negatively regulates the development of interleukin 17\u2013producing T helper cells during chronic inflammation of the central nervous system. Nature Immunology 7 (9): 937\u2013945.", "ArticleIdList": ["10.1038/ni1376", "16906166"]}, {"Citation": "Momtaz, S., et al. 2021. Cinnamaldehyde targets TLR-4 and inflammatory mediators in acetic-acid induced ulcerative colitis model. Biologia 76 (6): 1817\u20131827.", "ArticleIdList": ["10.1007/s11756-021-00725-w"]}, {"Citation": "Nasiri, A., et al. 2021. Evaluation of the relationship among the levels of SIRT1 and SIRT3 with oxidative stress and DNA fragmentation in asthenoteratozoospermic men. International Journal of Fertility & Sterility 15 (2): 135."}, {"Citation": "Matheson, N., P. Wong, and J. Travis. 1981. Isolation and properties of human neutrophil myeloperoxidase. Biochemistry 20 (2): 325\u2013330.", "ArticleIdList": ["10.1021/bi00505a015", "6258635"]}, {"Citation": "Ghasemi-Niri, S., et al. 2011. On the benefit of whey-cultured Lactobacillus casei in murine colitis. Journal of Physiology and Pharmacology 62 (3): 341.", "ArticleIdList": ["21893695"]}, {"Citation": "Bradford, M.M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 (1\u20132): 248\u2013254.", "ArticleIdList": ["10.1016/0003-2697(76)90527-3", "942051"]}, {"Citation": "Khan, I., M.A. Oriowo, and J.T. Anim. 2005. Amelioration of experimental colitis by Na-H exchanger-1 inhibitor amiloride is associated with reversal of IL-1ss and ERK mitogen-activated protein kinase. Scandinavian Journal of Gastroenterology 40 (5): 578\u201385.", "ArticleIdList": ["10.1080/00365520510012352", "16036511"]}, {"Citation": "Janakiram, N.B. and C.V. Rao. 2014. The role of inflammation in colon cancer. Inflammation and Cancer 25-52."}, {"Citation": "Kmie\u0107, Z., M. Cyman, and T.J. \u015alebioda. 2017. Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease. Advances in Medical Sciences 62 (1): 1\u201316.", "ArticleIdList": ["10.1016/j.advms.2016.09.001", "28126697"]}, {"Citation": "Rashidian, A., et al. 2019. Agmatine ameliorates acetic acid-induced colitis in rats: involvement of nitrergic system. Immunopharmacol Immunotoxicol 41 (2): 242\u2013249.", "ArticleIdList": ["10.1080/08923973.2019.1578973", "30821531"]}, {"Citation": "Zhang, T., et al. 2021. Randomized controlled trial: perioperative dexamethasone reduces excessive postoperative inflammatory response and ileus after surgery for inflammatory bowel disease. Inflammatory Bowel Disease 27 (11): 1756\u20131765.", "ArticleIdList": ["10.1093/ibd/izab065"]}, {"Citation": "Dejban, P., et al. 2021. Anti-inflammatory effect of amitriptyline in a rat model of acetic acid-induced colitis: the involvement of the TLR4/NF-kB signaling pathway. Fundamental and Clinical Pharmacology 35 (5): 843\u2013851.", "ArticleIdList": ["10.1111/fcp.12642", "33336463"]}, {"Citation": "Hur, S.J., et al. 2012. Review of natural products actions on cytokines in inflammatory bowel disease. Nutrition Research Reviews 32 (11): 801\u201316.", "ArticleIdList": ["10.1016/j.nutres.2012.09.013"]}, {"Citation": "Wu, Y.J., M. Xue, and H. Chen. 2012. Licofelone inhibits interleukin-18-induced pro-inflammatory cytokine release and cellular proliferation in human mesangial cells. Basic and Clinical Pharmacology and Toxicology 111 (3): 166\u201372.", "ArticleIdList": ["22433003"]}, {"Citation": "Ibrahim, S., et al. 2020. PIK3R3 regulates ZO-1 expression through the NF-kB pathway in inflammatory bowel disease. International immunopharmacology 85."}, {"Citation": "Kim, Y.J., E.H. Kim, and K.B. Hahm. 2012. Oxidative stress in inflammation-based gastrointestinal tract diseases: challenges and opportunities. The Journal of Gastroenterology and Hepatology 27 (6): 1004\u201310.", "ArticleIdList": ["10.1111/j.1440-1746.2012.07108.x", "22413852"]}, {"Citation": "Gupta, A., A. Kumar, and S.K. Kulkarni. 2010. Licofelone attenuates MPTP-induced neuronal toxicity: behavioral, biochemical and cellular evidence. Inflammopharmacology 18 (5): 223\u201332.", "ArticleIdList": ["10.1007/s10787-010-0052-6", "20697819"]}, {"Citation": "Wu, B., Q.H. Sodji, and A.K. Oyelere. 2022. Inflammation, fibrosis and cancer: mechanisms, therapeutic options and challenges. Cancers (Basel) 14(3)."}, {"Citation": "Thippeswamy, B.S., et al. 2011. Protective effect of embelin against acetic acid induced ulcerative colitis in rats. European Journal of Pharmacology 654 (1): 100\u20135.", "ArticleIdList": ["10.1016/j.ejphar.2010.12.012", "21185828"]}, {"Citation": "Gonz\u00e1lez, R., et al. 1999. Anti-inflammatory activity of phycocyanin extract in acetic acid-induced colitis in rats. Pharmacological Research 39 (1): 55\u20139.", "ArticleIdList": ["10.1006/phrs.1998.0409", "10366332"]}, {"Citation": "Hosseini, R., et al. 2022. Effect of sumatriptan on acetic acid-induced experimental colitis in rats: a possible role for the 5-HT(1B/1D) receptors. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology 395 (5): 563\u2013577.", "ArticleIdList": ["10.1007/s00210-022-02215-5", "35171300"]}, {"Citation": "Kumar, P., H. Kalonia, and A. Kumar. 2011. Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington\u2019s disease-like symptoms in rats: protective effect of licofelone. British Journal of Pharmacology 164 (2b): 644\u201354.", "ArticleIdList": ["10.1111/j.1476-5381.2011.01418.x", "21486276", "3188893"]}, {"Citation": "Fakhraei, N., et al. 2014. Protective effect of hydroalcoholic olive leaf extract on experimental model of colitis in rat: involvement of nitrergic and opioidergic systems. Phytotherapy Research 28 (9): 1367\u201373.", "ArticleIdList": ["10.1002/ptr.5139", "24590915"]}, {"Citation": "Triantafillidis, J.K., G. Nasioulas, and P.A. Kosmidis. 2009. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Research 29 (7): 2727\u201337.", "ArticleIdList": ["19596953"]}, {"Citation": "Andersen, V., J. Halfvarson, and U. Vogel. 2012. Colorectal cancer in patients with inflammatory bowel disease: can we predict risk? World Journal of Gastroenterology 18 (31): 4091\u20134.", "ArticleIdList": ["10.3748/wjg.v18.i31.4091", "22919240", "3422788"]}, {"Citation": "Soni, J.M., et al. 2021. Melatonin-loaded chitosan nanoparticles endows nitric oxide synthase 2 mediated anti-inflammatory activity in inflammatory bowel disease model. Materials Science and Engineering 124."}, {"Citation": "Bias, P., et al. 2004. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. American Journal of Gastroenterology 99 (4): 611\u20138.", "ArticleIdList": ["10.1111/j.1572-0241.2004.04133.x", "15089890"]}, {"Citation": "Tavolari, S., et al. 2008. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis 29 (2): 371\u201380.", "ArticleIdList": ["10.1093/carcin/bgm265", "18033773"]}], "ReferenceList": [], "Title": "REFERENCES"}], "History": [{"Year": "2023", "Month": "1", "Day": "28"}, {"Year": "2023", "Month": "5", "Day": "11"}, {"Year": "2023", "Month": "5", "Day": "2"}, {"Year": "2023", "Month": "10", "Day": "23", "Hour": "12", "Minute": "44"}, {"Year": "2023", "Month": "5", "Day": "26", "Hour": "13", "Minute": "9"}, {"Year": "2023", "Month": "5", "Day": "26", "Hour": "11", "Minute": "12"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37233919", "10.1007/s10753-023-01835-0", "10.1007/s10753-023-01835-0"]}}], "PubmedBookArticle": []}